Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Accumulated Expenses (2016 - 2017)

Agios Pharmaceuticals (AGIO) has disclosed Other Accumulated Expenses for 6 consecutive years, with $1.3 million as the latest value for Q1 2017.

  • For Q1 2017, Other Accumulated Expenses rose 386.84% year-over-year to $1.3 million; the TTM value through Mar 2017 reached $1.3 million, up 386.84%, while the annual FY2016 figure was $168000.0, 87.21% down from the prior year.
  • Other Accumulated Expenses hit $1.3 million in Q1 2017 for Agios Pharmaceuticals, up from $168000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $1.3 million in Q4 2015 and bottomed at $6000.0 in Q4 2014.
  • Average Other Accumulated Expenses over 5 years is $417000.0, with a median of $311000.0 recorded in 2015.
  • Year-over-year, Other Accumulated Expenses plummeted 94.44% in 2014 and then soared 21800.0% in 2015.
  • Agios Pharmaceuticals' Other Accumulated Expenses stood at $9000.0 in 2013, then tumbled by 33.33% to $6000.0 in 2014, then skyrocketed by 21800.0% to $1.3 million in 2015, then plummeted by 87.21% to $168000.0 in 2016, then soared by 670.83% to $1.3 million in 2017.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $1.3 million, $168000.0, and $538000.0 for Q1 2017, Q4 2016, and Q3 2016 respectively.